Mutations in KIT, BRAF, NRAS and cyclin-dependent kinase inhibitor 2A (CDKN2A) also participate in melanoma progression [11] as do mutations that lead to excessive PI3K-Akt signaling [12]. The gene discussed is CDKN2A; the disease is melanoma.